US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CytomX Therapeutics

0.6560

+0.02634.18%

Post-market: 0.67000.0140+2.13%18:45 EDT

Volume:580.90K

Turnover:376.62K

Market Cap:52.55M

PE:1.74

High:0.6695

Open:0.6286

Low:0.6100

Close:0.6297

Loading ...

Overview Company News Filings

SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies

CytomX Therapeutics Is Maintained at Overweight by Piper Sandler

FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug

SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy

BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study

CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal

CytomX Therapeutics participates in a conference call with JPMorgan

FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda

FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib

Elevation Oncology Plunges 42% on Ending Development of Lead Drug

Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering

Top Executives Cash Out: CytomX Therapeutics Stock Transactions Unveiled!

SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion

AMGN Posts Upbeat Data on Uplizna From Myasthenia Gravis Study

Allogene's Q4 Loss Narrower Than Expected, Revenues Nil

CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know

CytomX Therapeutics Full Year 2024 Earnings: Beats Expectations

Simply Wall St.

CytomX Therapeutics Faces Critical Challenges in Product Development and Market Viability

CytomX Therapeutics’ Earnings Call Highlights Progress and Challenges

CytomX Therapeutics, Inc. (CTMX): Among the Cheap Growth Stocks to Buy Now

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CTMX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CTMX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTMX\",,,,,undefined,":{"symbol":"CTMX","market":"US","secType":"STK","nameCN":"CytomX Therapeutics","latestPrice":0.656,"timestamp":1744920000000,"preClose":0.6297,"halted":0,"volume":580902,"hourTrading":{"tag":"盘后","latestPrice":0.67,"preClose":0.656,"latestTime":"18:45 EDT","volume":18581,"amount":12350.14478,"timestamp":1744929939239},"delay":0,"floatShares":73975171,"shares":80099889,"eps":0.377419,"marketStatus":"Closed Good Friday","change":0.0263,"latestTime":"04-17 16:00:00 EDT","open":0.6286,"high":0.6695,"low":0.61,"amount":376622.96697732003,"amplitude":0.094489,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.377419,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1444276800000,"exchange":"NASDAQ","adjPreClose":0.6297,"preHourTrading":{"tag":"盘前","latestPrice":0.63,"preClose":0.6297,"latestTime":"09:22 EDT","volume":4047,"amount":2573.9701071,"timestamp":1744896120437},"postHourTrading":{"tag":"盘后","latestPrice":0.67,"preClose":0.656,"latestTime":"18:45 EDT","volume":18581,"amount":12350.14478,"timestamp":1744929939239},"volumeRatio":0.623138,"impliedVol":1.7576,"impliedVolPercentile":0.6135},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTMX\",,,,,undefined,":{"symbol":"CTMX","floatShares":73975171,"roa":"9.69%","roe":"-139.27%","lyrEps":0.377419,"volumeRatio":0.623138,"shares":80099889,"dividePrice":0,"high":0.6695,"amplitude":0.094489,"preClose":0.6297,"low":0.61,"week52Low":0.4,"pbRate":"-115.23","psRate":"0.38","week52High":5.85,"institutionHeld":0,"latestPrice":0.656,"eps":0.377419,"divideRate":0,"volume":580902,"delay":0,"ttmEps":0.377419,"open":0.6286,"prevYearClose":1.03,"prevWeekClose":0.5325,"prevMonthClose":0.6358,"prevQuarterClose":0.6358,"fiveDayClose":0.4946,"twentyDayClose":0.6659,"sixtyDayClose":0.8379},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CTMX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527217592","title":"SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2527217592","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527217592?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:32","pubTimestamp":1744803120,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics SRPT announced updates from its clinical programs, which focus on targeting different subtypes of limb-girdle muscular dystrophy , a group of rare genetic disorders marked by progressive muscle weakness.Following positive FDA feedback, the company is advancing a fourth LGMD program to clinical development. Sarepta will soon start screening and dosing patients in the first-in-human clinical SRP-9005-101  study, to evaluate its investigational gene therapy SRP-9005 for LGMD type 2C/R5 .SRPT also announced completion of enrollment and dosing in the phase I proof-of-concept SRP-9004-102  study, which is evaluating SRP-9004 in patients with LGMD type 2D/R3 .The company also reiterated its plans to report data from the late-stage EMERGENE study, evaluating SRP-9003 in patients with LGMD type 2E/R4 , by first-half 2025. This study’s primary endpoint is the biomarker expression of the beta-sarcoglycan protein, whose absence is the sole cause of the disease. Following a pre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/srpt-provides-pipeline-updates-rare-113200363.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0566484027.USD","ANIP","IE0009355771.USD","SRPT","RHHBY","CTMX","IE00BJT1NW94.SGD","BK4007","IE0002141913.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","BK4585","IE00B2B36J28.USD","LU1559883803.SGD","03165","BK4139"],"gpt_icon":0},{"id":"2527196931","title":"CytomX Therapeutics Is Maintained at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2527196931","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527196931?lang=en_us&edition=fundamental","pubTime":"2025-04-14 22:59","pubTimestamp":1744642740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CTMX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 14, 2025 10:59 ET (14:59 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTMX"],"gpt_icon":0},{"id":"2525318890","title":"FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2525318890","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525318890?lang=en_us&edition=fundamental","pubTime":"2025-04-08 18:46","pubTimestamp":1744109160,"startTime":"0","endTime":"0","summary":"Allogene Therapeutics ALLO announced that the FDA has granted three fast track designations to its investigational CRISPR-based allogeneic CAR-T therapy, ALLO-329.These designations apply to three autoimmune diseases — systemic lupus erythematosus , idiopathic inflammatory myopathy  and diffuse systemic sclerosis .How Does the Fast Track Tag Benefit ALLO’s Drug Development?Fast track designation is designed to facilitate the development and expedite the review of drugs that treat serious conditions, meet an unmet medical need, or offer a potential advantage over existing treatments. Per the FDA, the purpose of granting this designation is to ‘get important new drugs to the patient earlier.’。In the past 60 days, estimates for CytomX Therapeutics’ 2025 EPS have improved from a loss of 31 cents to a profit of 25 cents. During the same timeframe, estimates for loss per share for 2026 have","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-grants-three-fast-track-104600523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BYQQ9H92.USD","BK4567","BK4077","BK4104","BK4588","IE00BFXG0V08.USD","BK4139","IIM","BK4007","ANIP","CTMX","FAST","IE00B5TLWC47.USD","ALLO","ETNB","BK4585","BK4505","SLE"],"gpt_icon":0},{"id":"2524420475","title":"SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2524420475","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524420475?lang=en_us&edition=fundamental","pubTime":"2025-04-04 19:29","pubTimestamp":1743766140,"startTime":"0","endTime":"0","summary":"Shares of Sarepta Therapeutics SRPT dropped more than 6% yesterday after the EMA placed a clinical hold on all studies evaluating Elevidys, its one-shot gene therapy for Duchenne muscular dystrophy . The therapy has been developed in collaboration with pharma giant Roche RHHBY.This hold has been placed in response to a patient’s death post-treatment with Elevidys, which was reported last month. Though the death was due to acute liver failure , Sarepta believes that the patient’s recent CMV infection might have contributed to the outcome. Investigation is still ongoing.In a letter to the World Duchenne Organization, Roche mentioned that the companies are pausing enrollment and dosing of study participants in three studies evaluating the therapy at the EU study sites. This hold will remain ‘until the analysis into the cause of death is complete.’。SRPT and RHHBY entered into a licensing agreement in 2019 to develop Elevidys. Per the agreement, Sarepta retains the rights to market the gene","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/srpt-stock-down-ema-places-112900759.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["03165","IE00BJJMRZ35.SGD","BK4007","IE00BJT1NW94.SGD","BK4139","RHHBY","IE0002141913.USD","SRPT","IE00BFTCPJ56.SGD","ANIP","BK4585","CTMX","IE0009355771.USD","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"2524260088","title":"BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2524260088","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524260088?lang=en_us&edition=fundamental","pubTime":"2025-04-03 22:14","pubTimestamp":1743689640,"startTime":"0","endTime":"0","summary":"BioMarin BMRN has announced positive results from the phase III PEGASUS study evaluating Palynziq  in adolescents aged 12-17 years with phenylketonuria .The study achieved its primary endpoint – patients treated with Palynziq achieved a statistically significant lowering in blood phenylalanine  levels compared to diet alone. The safety results were also consistent with the known profile of the drug.Palynziq is already approved in the United States to reduce blood Phe concentration in adults aged 18 years and older with PKU. The drug is currently the only enzyme therapy to treat the disease in this age group.PKU is a rare genetic disorder that prevents the body from breaking down Phe, an amino acid found in protein-rich foods, leading to toxic levels that can cause severe neurological damage. While newborn screening enables early diagnosis, lifelong dietary management is challenging, creating demand for innovative treatments like those developed by BioMarin.In the past 60 days, estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bmrns-pku-drug-palynziq-meets-141400981.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IE00B19Z3581.USD","IE00B7SZLL34.SGD","BK4566","BMRN","CTMX","SSI","BK4585","IE0002270589.USD","ETNB","IE00B19Z3B42.SGD","BK4007","ANIP"],"gpt_icon":0},{"id":"2524128774","title":"CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2524128774","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524128774?lang=en_us&edition=fundamental","pubTime":"2025-04-01 22:50","pubTimestamp":1743519000,"startTime":"0","endTime":"0","summary":"Shares of Corcept Therapeutics Incorporated CORT were up a staggering 109.1% on March 31 after the company announced data from the phase III ROSELLA study, which evaluated its pipeline candidate, relacorilant, in combination with nab-paclitaxel for treating patients with platinum-resistant ovarian cancer.The ROSELLA study met its primary endpoint of improved progression-free survival, as assessed by blinded independent central review .Per management, data from the ROSELLA study suggested that the combo of relacorilant plus nab-paclitaxel has the potential to become a new standard of care for patients with platinum-resistant ovarian cancer.Year to date, shares of Corcept have skyrocketed 126.7% against the industry’s decline of 1.9%.The phase III ROSELLA study evaluated relacorilant in combination with nab-paclitaxel for treating patients with recurrent, platinum-resistant ovarian cancer.Data from the same showed that treatment with relacorilant plus nab-paclitaxel reduced the risk of d","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cort-shares-rise-relacorilant-combo-145000011.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065170008.USD","FOLD","LU0566484027.USD","BK4139","BK4097","LU2065171402.SGD","ANIP","CTMX","LU2065169927.USD","LU2065171311.SGD","LU1559883803.SGD","CORT","OS","BK4007","BK4532"],"gpt_icon":0},{"id":"2524228059","title":"CytomX Therapeutics participates in a conference call with JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2524228059","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524228059?lang=en_us&edition=fundamental","pubTime":"2025-03-31 23:50","pubTimestamp":1743436214,"startTime":"0","endTime":"0","summary":"Conference call with address top 10 questions in management on March 31 at 12 pm hosted by PMorgan. Webcast Link Published first on TheFly – the ul...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cytomx-therapeutics-participates-in-a-conference-call-with-jpmorgan-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cytomx-therapeutics-participates-in-a-conference-call-with-jpmorgan-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","LU0211331839.USD","LU0320765489.SGD","LU1720051108.HKD","IE00BBT3K403.USD","LU2023250504.SGD","BK4534","IE00BJLML261.HKD","LU1894683264.USD","LU0170899867.USD","BK4504","LU0203345920.USD","BK4566","LU1145028129.USD","LU1162221912.USD","SG9999002224.SGD","LU1551013425.SGD","IE00B775SV38.USD","LU1720051017.SGD","LU2357305700.SGD","LU0149725797.USD","LU1366192091.USD","LU2264538146.SGD","IE00BKVL7J92.USD","IE00BWXC8680.SGD","IE00BKDWB100.SGD","LU2242649171.HKD","LU0496365809.HKD","IE00BDRTCR15.USD","LU0820562030.AUD","LU0964807845.USD","BK4588","LU1064131342.USD","LU2237443465.HKD","IE000M9KFDE8.USD","CTMX","BK4550","LU1244550221.USD","LU0211328371.USD","LU2552382058.USD","LU2552382215.SGD","LU0211326839.USD","LU2430703251.USD","LU2237443549.SGD","LU2237443895.HKD","LU1668664300.SGD","LU2106854487.HKD","LU0215105999.USD","LU1629891620.HKD"],"gpt_icon":0},{"id":"2523685649","title":"FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda","url":"https://stock-news.laohu8.com/highlight/detail?id=2523685649","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523685649?lang=en_us&edition=fundamental","pubTime":"2025-03-28 23:20","pubTimestamp":1743175200,"startTime":"0","endTime":"0","summary":"Merck MRK announced that the FDA has accepted its regulatory filing seeking approval for the subcutaneous  formulation of the blockbuster drug Keytruda .This filing seeks the agency’s nod for the SC version across all solid tumor indications for which the drug’s intravenous  version is already approved.A final decision is expected by Sept. 23, 2025.The regulatory filing is supported by data from the pivotal phase III 3475A-D77 study that evaluated Keytruda SC against the IV version  for the first-line treatment of adult patients with metastatic non-small cell lung cancer. As announced by Merck in November, the study achieved its primary endpoints, showing that the treatment with the SC version of the drug was at least as effective as the IV version.An approval of the SC version also benefits both patients and physicians. Delivering a drug SC instead of IV can significantly reduce administrat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-accepts-mercks-filing-subcutaneous-152000184.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE000M9KFDE8.USD","LU1934455863.HKD","IE00BJJMRZ35.SGD","IE00BLSP4239.USD","LU1116320737.USD","CTMX","LU0320765489.SGD","LU0266013472.USD","BK4516","BK4139","ANIP","IE00BJT1NW94.SGD","LU1037948897.HKD","LU2112291526.USD","LU1037948541.HKD","LU0058720904.USD","LU2361044865.SGD","LU0985320562.USD","SG9999002224.SGD","LU0289739699.SGD","LU2023250843.SGD","LU1989772923.USD","IE00BSNM7G36.USD","IE00BN8TJ469.HKD","SG9999015341.SGD","LU1989772840.SGD","LU1941712264.USD","SG9999014575.USD","BK4585","LU0965509010.AUD","MRK","IE0002141913.USD","LU0861579265.USD","LU1023059063.AUD","LU0070302665.USD","SG9999001176.SGD","LU0208291251.USD","LU0965509283.SGD","LU1066053197.SGD","LU1066051811.HKD","LU1066051498.USD","LU1585245621.USD","IE00B4R5TH58.HKD","LU1093756325.SGD","SG9999015358.SGD","ETNB","LU0320765646.SGD","LU1983299246.USD","BK4550"],"gpt_icon":0},{"id":"2522079582","title":"FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2522079582","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522079582?lang=en_us&edition=fundamental","pubTime":"2025-03-25 19:56","pubTimestamp":1742903760,"startTime":"0","endTime":"0","summary":"Sanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis  and slow disability accumulation independent of relapse activity in adults.The filing has been granted priority review by the FDA, bringing down the review period by four months. A final decision is expected by Sept. 28, 2025.The FDA filing is supported by data from three late-stage studies — one  in nrSPMS and two  in relapsing MS . Data from these studies showed that patients treated with tolebrutinib delayed the time to onset of six-month confirmed disability progression when compared to placebo. A similar regulatory filing for the drug is currently under review by the EMA, which is also supported by data from these studies.Per Sanofi, the above results make tolebrutinib the first and the only brain-penetrant BTK inhibitor to treat both the above MS indications. If approved, tolebruti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-accepts-sanofis-filing-multiple-115600487.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4534","BK4588","LU2028103732.USD","LU0106831901.USD","BK4581","LU1720051108.HKD","LU0912757837.SGD","BK4123","LU0225283273.USD","ETNB","LU0158827948.USD","LU1668664300.SGD","LU1989772840.SGD","LU2111349929.HKD","LU1732800096.USD","LU2089283258.USD","LU1162221912.USD","IE00B66KJ199.SGD","LU0158827781.USD","LU2023251221.USD","IE00BZ1G4Q59.USD","IE00B19Z4B17.USD","LU0098860793.USD","LU1548497426.USD","LU2133065610.SGD","LU2271345857.HKD","LU0106261372.USD","BK4139","ANIP","BK4585","LU1363072403.SGD","LU1720051017.SGD","CTMX","IE00BFXG1179.USD","LU2357305700.SGD","BK4504","LU0971096721.USD","IE00BKVL7J92.USD","MG","LU1732799900.SGD","SNY","LU0267386448.USD","LU0314104364.USD","SNYNF","LU0320765646.SGD","LU1074936037.SGD","LU0795875169.SGD","BK4516","IE0031619046.USD"],"gpt_icon":0},{"id":"2521940256","title":"Elevation Oncology Plunges 42% on Ending Development of Lead Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2521940256","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521940256?lang=en_us&edition=fundamental","pubTime":"2025-03-22 01:03","pubTimestamp":1742576580,"startTime":"0","endTime":"0","summary":"Shares of Elevation Oncology ELEV plunged more than 40% yesterday after reporting disappointing data from a phase I study on its lead pipeline drug EO-3021 for treating advanced, unresectable or metastatic gastric and gastroesophageal junction  cancers.Data from the study showed that patients who were treated with ELEV’s lead drug showed an objective response rate  of 22.2% —out of 36 evaluable patients, there was one complete response and seven partial responses.Following the disappointing study results, Elevation Oncology decided not to pursue further clinical development of EO-3021. Instead, the company will now shift its focus to solid tumor candidate EO-1022, for which an investigational new drug  filing with the FDA is expected next year. As a result of this decision, ELEV is now without a pipeline candidate in clinical development. These factors were likely responsible for the significant drop in share price.In the past 60 days, estimates for CytomX Therapeutics’ 2025 EPS have i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/elevation-oncology-plunges-42-ending-170300990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4007","ELEV","ORR","ANIP","BK4539","CTMX","BK4139","ETNB"],"gpt_icon":0},{"id":"2521946256","title":"Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2521946256","media":"Zacks","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521946256?lang=en_us&edition=fundamental","pubTime":"2025-03-22 01:01","pubTimestamp":1742576460,"startTime":"0","endTime":"0","summary":"Akebia Therapeutics AKBA recently announced that it is floating a secondary issue of 25 million shares of its common stock to the public at an issue price of $2 per share, amounting to $50 million.The company also granted an option to underwriters of the issue to purchase an additional 3.75 million shares at the same price.The secondary offering is expected to close today.Akebia’s shares fell more than 28% yesterday after the announcement. Though the issue does not significantly dilute the existing shareholder base, the issue price per share did not sit well with investors. The issue price was at a discount to the closing price on Thursday, with the stock closing at $2.04.Year to date, shares of Akebia have outperformed the industry.Akebia plans to use the net proceeds from this new issue and its existing cash balance to fund working capital and general corporate purposes, which may include supporting research, development and commercial activities for its marketed and pipeline drugs.A","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/akebia-stock-drops-28-pricing-170100693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTMX","BK4007","AKBA","ETNB","ANIP","BK4139","BK4585"],"gpt_icon":0},{"id":"2521844926","title":"Top Executives Cash Out: CytomX Therapeutics Stock Transactions Unveiled!","url":"https://stock-news.laohu8.com/highlight/detail?id=2521844926","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521844926?lang=en_us&edition=fundamental","pubTime":"2025-03-21 10:04","pubTimestamp":1742522673,"startTime":"0","endTime":"0","summary":"New insider activity at CytomX Therapeutics ( ($CTMX) ) has taken place on March 21, 2025. In recent transactions involving CytomX Therapeutics sto...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-executives-cash-out-cytomx-therapeutics-stock-transactions-unveiled?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-executives-cash-out-cytomx-therapeutics-stock-transactions-unveiled?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTMX","BK4139"],"gpt_icon":0},{"id":"2520160326","title":"SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion","url":"https://stock-news.laohu8.com/highlight/detail?id=2520160326","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520160326?lang=en_us&edition=fundamental","pubTime":"2025-03-20 01:38","pubTimestamp":1742405880,"startTime":"0","endTime":"0","summary":"Per the company, this patient died of acute liver failure. While acute liver injury is a known risk of Elevidys, this is the first time a death has been reported of anyone taking the therapy. However, Sarepta stated that the patient also had a recent CMV infection, which may have contributed to the outcome, as CMV can damage the liver.Sarepta has reported the event to health authorities, clinical study investigators and prescribing physicians. It intends to update Elevidys’ prescribing information accordingly. Despite the incident, the company maintains that the benefit-risk profile of its gene therapy remains positive, with over 800 patients treated in clinical studies or commercial use.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/srpt-nosedives-27-patient-death-173800583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SRPT","IE00BJT1NW94.SGD","ANIP","IE00BFTCPJ56.SGD","CTMX","IE0002141913.USD","BK4585","03165","BK4139","IE0009355771.USD","BK4007","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","RHHBY"],"gpt_icon":0},{"id":"2520066845","title":"AMGN Posts Upbeat Data on Uplizna From Myasthenia Gravis Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2520066845","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520066845?lang=en_us&edition=fundamental","pubTime":"2025-03-18 00:05","pubTimestamp":1742227500,"startTime":"0","endTime":"0","summary":"Amgen AMGN reported the latest data from the phase III MINT study that evaluated the rare disease drug Uplizna  for label expansion in generalized myasthenia gravis  indication.Data from the study showed that treatment with Uplizna ‘demonstrated durable and sustained efficacy’ in AChR-positive  gMG patients over 52 weeks. These findings were assessed using the Myasthenia Gravis Activities of Daily Living  scores, a patient-reported tool that measures the impact of the disease’s symptoms on a person's ability to perform daily activities. Patients treated with Uplizna for a year showed a 2.8-point improvement over placebo. Per Amgen, about 72% of AChR+ patients in the Uplizna group had an improvement of three or more points in the MG-ADL score compared to 45% in the placebo group.There was also a change in the Quantitative Myasthenia Gravis  score, a physician assessment tool for quantifying disease severity. 69% of AChR+ patients treated with Uplizna showed an improvement of three or mo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgn-posts-upbeat-data-uplizna-160500075.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BFTCPJ56.SGD","CTMX","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU1023059063.AUD","LU1061106388.HKD","BK4139","LU0122379950.USD","BK4581","BK4588","LU0320765992.SGD","LU0058720904.USD","BK4599","IE0002141913.USD","LU1057294990.SGD","LU0868494617.USD","LU2112291526.USD","ANIP","BK4585","SG9999001440.SGD","IE0009355771.USD","IE00BJJMRZ35.SGD","LU2242652126.USD","ARGX","BK4505","LU1983299246.USD","LU0109394709.USD","IE00B4R5TH58.HKD","AMGN","LU2242646821.SGD","BK4533","LU1571399168.USD","LU0889565916.HKD","BK4566","LU0289739699.SGD","BK4007","BK4534"],"gpt_icon":0},{"id":"2519015098","title":"Allogene's Q4 Loss Narrower Than Expected, Revenues Nil","url":"https://stock-news.laohu8.com/highlight/detail?id=2519015098","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519015098?lang=en_us&edition=fundamental","pubTime":"2025-03-14 19:52","pubTimestamp":1741953120,"startTime":"0","endTime":"0","summary":"Allogene Therapeutics ALLO incurred a loss of 28 cents per share in fourth-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of 34 cents. In the year-ago period, the company had incurred a loss of 51 cents per share.See the Zacks Earnings Calendar to stay ahead of market-making news.ALLO did not generate revenues during the reported quarter. The Zacks Consensus Estimate for fourth-quarter sales was pegged at $0.07 million. In the year-ago period, the company recorded revenues of $0.02 million.Year to date, shares of Allogene have lost 11% against the industry’s 6% growth.Research & development (R&D) expenses totaled $45 million, down 18% from the year-ago quarter’s level.General and administrative (G&A) expenses declined 10% year over year to $15.5 million.As of Dec. 31, 2024, Allogene had $373.1 million of cash, cash equivalents and investments, compared with $403.4 million as of Sept. 30, 2024. The company claims that its cash runway will fund operations into the sec","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/allogenes-q4-loss-narrower-expected-115200427.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTMX","ALLO"],"gpt_icon":0},{"id":"2518677986","title":"CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2518677986","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518677986?lang=en_us&edition=fundamental","pubTime":"2025-03-12 00:00","pubTimestamp":1741708809,"startTime":"0","endTime":"0","summary":"CytomX Therapeutics  could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 . This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.As such, the Zacks rating upgrade for CytomX Therapeutics is essentially a positive comment on its earnings outlook that could have a favorable impact on its s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cytomx-therapeutics-ctmx-upgraded-strong-160009668.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTMX"],"gpt_icon":0},{"id":"2517445098","title":"CytomX Therapeutics Full Year 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2517445098","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517445098?lang=en_us&edition=fundamental","pubTime":"2025-03-08 20:10","pubTimestamp":1741435817,"startTime":"0","endTime":"0","summary":"Profit margin: 23% . The move to profitability was driven by higher revenue.NasdaqGS:CTMX Earnings and Revenue Growth March 8th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 19%. Earnings per share  also surpassed analyst estimates.Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 20% growth forecast for the Biotechs industry in the US.The company's shares are down 1.8% from a week ago.Don't forget that there may still be risks. For instance, we've identified   4 warning signs for CytomX Therapeutics   you should be aware of.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cytomx-therapeutics-full-2024-earnings-121017859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTMX"],"gpt_icon":0},{"id":"2517416161","title":"CytomX Therapeutics Faces Critical Challenges in Product Development and Market Viability","url":"https://stock-news.laohu8.com/highlight/detail?id=2517416161","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517416161?lang=en_us&edition=fundamental","pubTime":"2025-03-08 14:02","pubTimestamp":1741413779,"startTime":"0","endTime":"0","summary":"CytomX Therapeutics Inc. (CTMX) has disclosed a new risk, in the Innovation / R&D category. CytomX Therapeutics Inc. faces significant business ris...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cytomx-therapeutics-faces-critical-challenges-in-product-development-and-market-viability?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cytomx-therapeutics-faces-critical-challenges-in-product-development-and-market-viability?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTMX","BK4139"],"gpt_icon":0},{"id":"2517934124","title":"CytomX Therapeutics’ Earnings Call Highlights Progress and Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2517934124","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517934124?lang=en_us&edition=fundamental","pubTime":"2025-03-08 08:11","pubTimestamp":1741392671,"startTime":"0","endTime":"0","summary":"CytomX Therapeutics Inc. (($CTMX)) has held its Q4 earnings call. Read on for the main highlights of the call. CytomX Therapeutics Inc. recently he...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cytomx-therapeutics-earnings-call-highlights-progress-and-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cytomx-therapeutics-earnings-call-highlights-progress-and-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTMX","PRGS"],"gpt_icon":0},{"id":"2517460966","title":"CytomX Therapeutics, Inc. (CTMX): Among the Cheap Growth Stocks to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2517460966","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517460966?lang=en_us&edition=fundamental","pubTime":"2025-03-08 07:45","pubTimestamp":1741391102,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Cheap Growth Stocks to Buy Now.In this article, we are going to take a look at where CytomX Therapeutics, Inc.  stands against the other cheap growth stocks.Growth stocks—those of companies expected to grow at an above-average rate compared to other firms—have historically exhibited cyclical performance patterns. For instance, during the 1990s dot-com era, growth stocks did well, as reported by Hartford Funds.Analysts suggest that stocks with a price-to-earnings (P/E) ratio below 15x often present attractive investment opportunities. These stocks may offer a combination of growth potential, driven by strong revenue and earnings expansion, as well as resilience, enabling them to perform well even in uncertain macroeconomic conditions.AsCharlie Munger aptly said, \"All intelligent investing is value investing—acquiring more than you are paying for. You must value the business in order to value the stock.\" This mindset aligns perfectly with identifying","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cytomx-therapeutics-inc-ctmx-among-234502039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USAW.SI","BK4139","BK4080",".IXIC","NVIW.SI","CTMX","TSYW.SI","BK4231","ADC","PSQ","SQQQ","TQQQ","MNQmain","NQmain","USJW.SI","QID","QLD"],"gpt_icon":1}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":114,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CTMX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-06","symbol":"CTMX","fiscalQuarterEnding":"2024/12","expectedEps":-0.2,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741237200000,"reportTimeType":"post","actualEps":0.22},{"market":"US","date":"2024-11-07","symbol":"CTMX","fiscalQuarterEnding":"2024/09","expectedEps":-0.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":0.07},{"market":"US","date":"2024-08-08","symbol":"CTMX","fiscalQuarterEnding":"2024/06","expectedEps":-0.07,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723089600000,"reportTimeType":"post","actualEps":-0.08},{"market":"US","date":"2024-05-08","symbol":"CTMX","fiscalQuarterEnding":"2024/03","expectedEps":-0.06,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"post","actualEps":0.17},{"market":"US","date":"2024-03-11","symbol":"CTMX","fiscalQuarterEnding":"2023/12","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1710129600000,"reportTimeType":"post","actualEps":0.01}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CTMX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CTMX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.3333,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.3333,"analysts":6,"updateTime":1716868800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CTMX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CTMX","date":"2025-04-16","current":1.587219,"percent":0.838103,"low":-610.657204,"twenty":-6.689406,"median":-2.286059,"eighty":-0.953028,"high":17.165432,"avg":-11.916361,"sd":52.493642,"marketCap":50583079},"quantilePoints":[{"date":"2020-04-24","current":-4.176951,"twenty":-20.987874,"median":-14.536056,"eighty":-5.772605,"marketCap":427043128},{"date":"2020-05-01","current":-5.035235,"twenty":-20.983929,"median":-14.52336,"eighty":-5.664817,"marketCap":514792323},{"date":"2020-05-08","current":-8.614874,"twenty":-20.96649,"median":-14.485274,"eighty":-5.651753,"marketCap":653946439},{"date":"2020-05-15","current":-5.450843,"twenty":-20.918622,"median":-14.471485,"eighty":-5.641954,"marketCap":413768077},{"date":"2020-05-22","current":-5.614187,"twenty":-20.869441,"median":-14.412035,"eighty":-5.625223,"marketCap":426167342},{"date":"2020-05-29","current":-5.360097,"twenty":-20.855205,"median":-14.387729,"eighty":-5.607113,"marketCap":406879596},{"date":"2020-06-05","current":-4.876115,"twenty":-20.837411,"median":-14.371018,"eighty":-5.579894,"marketCap":370141032},{"date":"2020-06-12","current":-4.815618,"twenty":-20.712849,"median":-14.355987,"eighty":-5.538565,"marketCap":365548711},{"date":"2020-06-19","current":-4.991061,"twenty":-20.67726,"median":-14.320237,"eighty":-5.498237,"marketCap":378866441},{"date":"2020-06-26","current":-4.960812,"twenty":-20.659465,"median":-14.307541,"eighty":-5.450843,"marketCap":376570281},{"date":"2020-07-02","current":-5.087857,"twenty":-20.576155,"median":-14.261373,"eighty":-5.410082,"marketCap":386214154},{"date":"2020-07-10","current":-5.15743,"twenty":-20.54514,"median":-14.219636,"eighty":-5.323504,"marketCap":391495322},{"date":"2020-07-17","current":-5.217927,"twenty":-20.527127,"median":-14.149251,"eighty":-5.258418,"marketCap":396087643},{"date":"2020-07-24","current":-4.694622,"twenty":-20.508161,"median":-14.129808,"eighty":-5.184654,"marketCap":356364070},{"date":"2020-07-31","current":-4.240889,"twenty":-20.453444,"median":-14.109343,"eighty":-5.169529,"marketCap":321921667},{"date":"2020-08-07","current":-5.620336,"twenty":-20.373286,"median":-14.106574,"eighty":-5.154405,"marketCap":351984762},{"date":"2020-08-14","current":-5.063465,"twenty":-20.352356,"median":-14.089783,"eighty":-5.154405,"marketCap":317109631},{"date":"2020-08-21","current":-5.126159,"twenty":-20.331137,"median":-14.019604,"eighty":-5.154405,"marketCap":321035970},{"date":"2020-08-28","current":-5.266299,"twenty":-20.312283,"median":-14.008481,"eighty":-5.154405,"marketCap":329812493},{"date":"2020-09-04","current":-4.838504,"twenty":-20.247683,"median":-13.96477,"eighty":-5.153195,"marketCap":303021002},{"date":"2020-09-11","current":-4.963892,"twenty":-20.22172,"median":-13.958967,"eighty":-5.109636,"marketCap":310873680},{"date":"2020-09-18","current":-5.458069,"twenty":-20.170596,"median":-13.951802,"eighty":-5.125358,"marketCap":341822472},{"date":"2020-09-25","current":-5.015523,"twenty":-20.11461,"median":-13.913989,"eighty":-5.067288,"marketCap":314107136},{"date":"2020-10-02","current":-4.772122,"twenty":-20.08008,"median":-13.899365,"eighty":-5.057355,"marketCap":298863702},{"date":"2020-10-09","current":-5.026586,"twenty":-20.064176,"median":-13.876559,"eighty":-5.053194,"marketCap":314800020},{"date":"2020-10-16","current":-5.059777,"twenty":-20.057081,"median":-13.857118,"eighty":-5.052064,"marketCap":316878670},{"date":"2020-10-23","current":-4.98602,"twenty":-20.043774,"median":-13.828188,"eighty":-5.029108,"marketCap":312259447},{"date":"2020-10-30","current":-4.882759,"twenty":-20.036656,"median":-13.801088,"eighty":-5.021444,"marketCap":305792536},{"date":"2020-11-06","current":-6.049502,"twenty":-20.01928,"median":-13.780006,"eighty":-5.018995,"marketCap":324495302},{"date":"2020-11-13","current":-6.376968,"twenty":-20.003719,"median":-13.762466,"eighty":-5.021444,"marketCap":342060574},{"date":"2020-11-20","current":-6.308028,"twenty":-19.990391,"median":-13.711175,"eighty":-5.022352,"marketCap":338362622},{"date":"2020-11-27","current":-6.394203,"twenty":-19.977759,"median":-13.596608,"eighty":-5.024373,"marketCap":342985062},{"date":"2020-12-04","current":-6.376968,"twenty":-19.969125,"median":-13.573758,"eighty":-5.026896,"marketCap":342060574},{"date":"2020-12-11","current":-6.532084,"twenty":-19.953786,"median":-13.48235,"eighty":-5.028526,"marketCap":350380967},{"date":"2020-12-18","current":-6.738904,"twenty":-19.927699,"median":-13.396874,"eighty":-5.032258,"marketCap":361474823},{"date":"2020-12-24","current":-6.394203,"twenty":-19.920158,"median":-13.309968,"eighty":-5.03608,"marketCap":342985062},{"date":"2020-12-31","current":-5.644479,"twenty":-19.913392,"median":-13.266804,"eighty":-5.039459,"marketCap":302769833},{"date":"2021-01-08","current":-6.376968,"twenty":-19.876131,"median":-13.133036,"eighty":-5.051559,"marketCap":342060574},{"date":"2021-01-15","current":-6.833697,"twenty":-19.875411,"median":-13.071715,"eighty":-5.052401,"marketCap":366559507},{"date":"2021-01-22","current":-7.50172,"twenty":-19.86922,"median":-13.049885,"eighty":-5.052401,"marketCap":402392271},{"date":"2021-01-29","current":-7.795021,"twenty":-19.846267,"median":-13.019446,"eighty":-5.053459,"marketCap":418124901},{"date":"2021-02-05","current":-9.390938,"twenty":-19.831701,"median":-12.942812,"eighty":-5.058566,"marketCap":503729902},{"date":"2021-02-12","current":-10.512244,"twenty":-19.824377,"median":-12.897211,"eighty":-5.059777,"marketCap":563876757},{"date":"2021-02-19","current":-10.418802,"twenty":-19.821989,"median":-12.77593,"eighty":-5.06199,"marketCap":558864519},{"date":"2021-02-26","current":-15.976239,"twenty":-19.809797,"median":-12.810718,"eighty":-5.063581,"marketCap":525378614},{"date":"2021-03-05","current":-15.833776,"twenty":-19.799678,"median":-12.921607,"eighty":-5.067288,"marketCap":520693709},{"date":"2021-03-12","current":-17.299112,"twenty":-19.76851,"median":-12.921607,"eighty":-5.067288,"marketCap":568881302},{"date":"2021-03-19","current":-16.831018,"twenty":-19.712796,"median":-12.921607,"eighty":-5.067288,"marketCap":553488043},{"date":"2021-03-26","current":-15.508145,"twenty":-19.620977,"median":-12.922693,"eighty":-5.068498,"marketCap":509985355},{"date":"2021-04-01","current":-16.016943,"twenty":-19.574255,"median":-12.922693,"eighty":-5.068498,"marketCap":526717158},{"date":"2021-04-09","current":-15.711664,"twenty":-19.474349,"median":-12.921607,"eighty":-5.067288,"marketCap":516678076},{"date":"2021-04-16","current":-15.284274,"twenty":-19.423718,"median":-12.921607,"eighty":-5.067288,"marketCap":502623362},{"date":"2021-04-23","current":-18.642337,"twenty":-19.348547,"median":-12.921607,"eighty":-5.067288,"marketCap":613053261},{"date":"2021-04-30","current":-18.502039,"twenty":-19.318728,"median":-12.921607,"eighty":-5.067288,"marketCap":608439564},{"date":"2021-05-07","current":-9.165707,"twenty":-19.246205,"median":-12.845506,"eighty":-5.067288,"marketCap":555845161},{"date":"2021-05-14","current":-8.747623,"twenty":-19.199134,"median":-12.654171,"eighty":-5.067288,"marketCap":530490820},{"date":"2021-05-21","current":-9.015626,"twenty":-19.199134,"median":-12.54111,"eighty":-5.067288,"marketCap":546743603},{"date":"2021-05-28","current":-7.67561,"twenty":-19.19054,"median":-12.410655,"eighty":-5.067288,"marketCap":465479690},{"date":"2021-06-04","current":-7.257525,"twenty":-19.109305,"median":-12.334551,"eighty":-5.067288,"marketCap":440125350},{"date":"2021-06-11","current":-7.67561,"twenty":-19.109305,"median":-12.217538,"eighty":-5.067288,"marketCap":465479690},{"date":"2021-06-18","current":-7.69705,"twenty":-19.109305,"median":-12.148707,"eighty":-5.067288,"marketCap":466779913},{"date":"2021-06-25","current":-6.914481,"twenty":-19.109305,"median":-12.059624,"eighty":-5.067288,"marketCap":419321788},{"date":"2021-07-02","current":-6.689358,"twenty":-19.101131,"median":-12.035228,"eighty":-5.067288,"marketCap":405669451},{"date":"2021-07-09","current":-6.507116,"twenty":-19.096054,"median":-12.010832,"eighty":-5.067288,"marketCap":394617559},{"date":"2021-07-16","current":-6.206953,"twenty":-19.021876,"median":-11.953909,"eighty":-5.067288,"marketCap":376414442},{"date":"2021-07-23","current":-5.94967,"twenty":-18.950858,"median":-11.888854,"eighty":-5.067288,"marketCap":360811771},{"date":"2021-07-30","current":-5.799588,"twenty":-18.890929,"median":-11.811434,"eighty":-5.067288,"marketCap":351710213},{"date":"2021-08-06","current":-5.327596,"twenty":-18.810436,"median":-11.750611,"eighty":-5.067288,"marketCap":342074265},{"date":"2021-08-13","current":-4.921684,"twenty":-18.643395,"median":-11.628633,"eighty":-5.057355,"marketCap":316011464},{"date":"2021-08-20","current":-4.728875,"twenty":-18.537367,"median":-11.542992,"eighty":-5.037769,"marketCap":303631633},{"date":"2021-08-27","current":-5.266709,"twenty":-18.470044,"median":-11.449731,"eighty":-5.033251,"marketCap":338164845},{"date":"2021-09-03","current":-5.21597,"twenty":-18.282192,"median":-11.400939,"eighty":-5.033251,"marketCap":334906995},{"date":"2021-09-10","current":-5.195674,"twenty":-18.214367,"median":-11.287092,"eighty":-5.033251,"marketCap":333603855},{"date":"2021-09-17","current":-5.3073,"twenty":-18.011705,"median":-11.171304,"eighty":-5.033251,"marketCap":340771125},{"date":"2021-09-24","current":-5.337744,"twenty":-17.880773,"median":-11.075663,"eighty":-5.033251,"marketCap":342725835},{"date":"2021-10-01","current":-5.185526,"twenty":-17.786094,"median":-11.006109,"eighty":-5.029108,"marketCap":332952285},{"date":"2021-10-08","current":-4.901388,"twenty":-17.593674,"median":-10.888629,"eighty":-5.022352,"marketCap":314708324},{"date":"2021-10-15","current":-5.21597,"twenty":-17.347957,"median":-10.734122,"eighty":-5.022352,"marketCap":334906995},{"date":"2021-10-22","current":-5.418926,"twenty":-17.286901,"median":-10.255278,"eighty":-5.022352,"marketCap":347938396},{"date":"2021-10-29","current":-6.017646,"twenty":-17.190067,"median":-10.091754,"eighty":-5.022352,"marketCap":386381027},{"date":"2021-11-05","current":-5.974365,"twenty":-17.127695,"median":-9.91655,"eighty":-5.022352,"marketCap":430644165},{"date":"2021-11-12","current":-6.354552,"twenty":-17.127695,"median":-9.702195,"eighty":-5.022352,"marketCap":458048794},{"date":"2021-11-19","current":-6.644218,"twenty":-17.127695,"median":-9.581303,"eighty":-5.022352,"marketCap":478928511},{"date":"2021-11-26","current":-6.110146,"twenty":-17.127695,"median":-9.533121,"eighty":-5.022352,"marketCap":440431533},{"date":"2021-12-03","current":-5.983417,"twenty":-17.127695,"median":-9.402102,"eighty":-5.022352,"marketCap":431296656},{"date":"2021-12-10","current":-5.693751,"twenty":-17.127695,"median":-9.370943,"eighty":-5.022352,"marketCap":410416939},{"date":"2021-12-17","current":-5.784271,"twenty":-17.127695,"median":-9.309923,"eighty":-5.022352,"marketCap":416941851},{"date":"2021-12-23","current":-3.819973,"twenty":-17.127695,"median":-9.214034,"eighty":-5.015418,"marketCap":275351269},{"date":"2021-12-31","current":-3.919545,"twenty":-17.127695,"median":-9.097316,"eighty":-4.989045,"marketCap":282528672},{"date":"2022-01-07","current":-3.521254,"twenty":-17.119715,"median":-9.010266,"eighty":-4.966268,"marketCap":253819061},{"date":"2022-01-14","current":-3.575567,"twenty":-17.119715,"median":-8.988637,"eighty":-4.961982,"marketCap":257734008},{"date":"2022-01-21","current":-3.883337,"twenty":-17.119715,"median":-8.85398,"eighty":-4.955638,"marketCap":279918707},{"date":"2022-01-28","current":-3.98291,"twenty":-17.119715,"median":-8.805781,"eighty":-4.940695,"marketCap":287096110},{"date":"2022-02-04","current":-3.856181,"twenty":-17.119715,"median":-8.758021,"eighty":-4.932273,"marketCap":277961234},{"date":"2022-02-11","current":-3.946702,"twenty":-17.119715,"median":-8.737148,"eighty":-4.904186,"marketCap":284486145},{"date":"2022-02-18","current":-3.711348,"twenty":-17.119715,"median":-8.689552,"eighty":-4.87848,"marketCap":267521375},{"date":"2022-02-25","current":-3.647983,"twenty":-17.119715,"median":-8.61807,"eighty":-4.874319,"marketCap":262953937},{"date":"2022-03-04","current":-2.093787,"twenty":-17.061962,"median":-8.407346,"eighty":-4.837766,"marketCap":242607132},{"date":"2022-03-11","current":-2.009133,"twenty":-17.009918,"median":-7.958591,"eighty":-4.791418,"marketCap":232798218},{"date":"2022-03-18","current":-1.811606,"twenty":-16.798456,"median":-7.750651,"eighty":-4.667881,"marketCap":209910753},{"date":"2022-03-25","current":-1.518137,"twenty":-16.708907,"median":-7.65953,"eighty":-4.531833,"marketCap":175906519},{"date":"2022-04-01","current":-1.58586,"twenty":-16.607213,"median":-7.518984,"eighty":-4.457209,"marketCap":183753649},{"date":"2022-04-08","current":-1.50685,"twenty":-16.57374,"median":-7.379808,"eighty":-4.397775,"marketCap":174598663},{"date":"2022-04-14","current":-1.303679,"twenty":-16.518509,"median":-7.230724,"eighty":-4.340581,"marketCap":151057270},{"date":"2022-04-22","current":-1.123083,"twenty":-16.311892,"median":-6.946642,"eighty":-4.261865,"marketCap":130131588},{"date":"2022-04-29","current":-0.965144,"twenty":-16.164988,"median":-6.796842,"eighty":-4.239985,"marketCap":111831187},{"date":"2022-05-06","current":-1.152331,"twenty":-16.037314,"median":-6.714191,"eighty":-4.169443,"marketCap":105945335},{"date":"2022-05-13","current":-1.251915,"twenty":-16.037314,"median":-6.648271,"eighty":-4.143215,"marketCap":115101104},{"date":"2022-05-20","current":-1.152331,"twenty":-16.037314,"median":-6.604751,"eighty":-4.08252,"marketCap":105945335},{"date":"2022-05-27","current":-1.152331,"twenty":-16.037314,"median":-6.566259,"eighty":-4.057616,"marketCap":105945335},{"date":"2022-06-03","current":-1.266142,"twenty":-16.037314,"median":-6.522189,"eighty":-4.032826,"marketCap":116409071},{"date":"2022-06-10","current":-1.323047,"twenty":-16.037314,"median":-6.480379,"eighty":-3.97927,"marketCap":121640940},{"date":"2022-06-17","current":-1.138105,"twenty":-16.037314,"median":-6.433323,"eighty":-3.95309,"marketCap":104637368},{"date":"2022-06-24","current":-1.3515,"twenty":-16.046011,"median":-6.408864,"eighty":-3.934785,"marketCap":124256874},{"date":"2022-07-01","current":-1.308821,"twenty":-16.046011,"median":-6.389195,"eighty":-3.9179,"marketCap":120332973},{"date":"2022-07-08","current":-0.92471,"twenty":-16.046011,"median":-6.376968,"eighty":-3.872475,"marketCap":85017861},{"date":"2022-07-15","current":-1.066973,"twenty":-16.046011,"median":-6.346314,"eighty":-3.809467,"marketCap":98097532},{"date":"2022-07-22","current":-1.031408,"twenty":-16.046011,"median":-6.316646,"eighty":-3.762177,"marketCap":94827614},{"date":"2022-07-29","current":-1.017181,"twenty":-16.046011,"median":-6.308028,"eighty":-3.738504,"marketCap":93519647},{"date":"2022-08-05","current":-1.130019,"twenty":-16.046011,"median":-6.26494,"eighty":-3.711348,"marketCap":109477401},{"date":"2022-08-12","current":-1.136827,"twenty":-16.046011,"median":-6.196,"eighty":-3.671605,"marketCap":110136904},{"date":"2022-08-19","current":-1.130019,"twenty":-16.046011,"median":-6.156937,"eighty":-3.629765,"marketCap":109477401},{"date":"2022-08-26","current":-1.041524,"twenty":-16.046011,"median":-6.121192,"eighty":-3.611561,"marketCap":100903870},{"date":"2022-09-02","current":-0.993872,"twenty":-16.046011,"median":-6.09259,"eighty":-3.569146,"marketCap":96287353},{"date":"2022-09-09","current":-1.089175,"twenty":-16.046011,"median":-6.049502,"eighty":-3.532316,"marketCap":105520387},{"date":"2022-09-16","current":-1.075561,"twenty":-16.046011,"median":-6.027794,"eighty":-3.511462,"marketCap":104201382},{"date":"2022-09-23","current":-0.97345,"twenty":-16.046011,"median":-5.997351,"eighty":-3.486665,"marketCap":94308846},{"date":"2022-09-30","current":-0.987065,"twenty":-16.046011,"median":-5.96096,"eighty":-3.449721,"marketCap":95627850},{"date":"2022-10-07","current":-0.953028,"twenty":-16.046011,"median":-5.928297,"eighty":-3.414806,"marketCap":92330338},{"date":"2022-10-14","current":-0.966643,"twenty":-16.046011,"median":-5.890191,"eighty":-3.396433,"marketCap":93649343},{"date":"2022-10-21","current":-0.905377,"twenty":-16.046011,"median":-5.862972,"eighty":-3.379973,"marketCap":87713821},{"date":"2022-10-28","current":-0.918992,"twenty":-16.046011,"median":-5.831748,"eighty":-3.331334,"marketCap":89032826},{"date":"2022-11-04","current":-0.850918,"twenty":-16.046011,"median":-5.784271,"eighty":-3.323074,"marketCap":82437802},{"date":"2022-11-11","current":-0.873514,"twenty":-16.046011,"median":-5.732321,"eighty":-3.273141,"marketCap":85248833},{"date":"2022-11-18","current":-1.178228,"twenty":-16.046011,"median":-5.677883,"eighty":-3.251622,"marketCap":114986798},{"date":"2022-11-25","current":-1.225628,"twenty":-16.046011,"median":-5.650664,"eighty":-3.224416,"marketCap":119612704},{"date":"2022-12-02","current":-1.157914,"twenty":-16.046011,"median":-5.620336,"eighty":-3.195939,"marketCap":113004267},{"date":"2022-12-09","current":-1.049571,"twenty":-16.046011,"median":-5.607113,"eighty":-3.110828,"marketCap":102430768},{"date":"2022-12-16","current":-1.063114,"twenty":-16.046011,"median":-5.569007,"eighty":-2.986764,"marketCap":103752456},{"date":"2022-12-23","current":-1.049571,"twenty":-16.046011,"median":-5.5407,"eighty":-2.919362,"marketCap":102430768},{"date":"2022-12-30","current":-1.083428,"twenty":-16.046011,"median":-5.520013,"eighty":-2.905032,"marketCap":105734987},{"date":"2023-01-06","current":-1.706399,"twenty":-16.021613,"median":-5.479813,"eighty":-2.876488,"marketCap":166532604},{"date":"2023-01-13","current":-1.936628,"twenty":-15.815007,"median":-5.458069,"eighty":-2.826882,"marketCap":189001289},{"date":"2023-01-20","current":-1.706399,"twenty":-15.672234,"median":-5.418926,"eighty":-2.80972,"marketCap":166532604},{"date":"2023-01-27","current":-1.875685,"twenty":-15.467441,"median":-5.400249,"eighty":-2.756449,"marketCap":183053696},{"date":"2023-02-03","current":-1.794428,"twenty":-15.286312,"median":-5.341948,"eighty":-2.654972,"marketCap":175123572},{"date":"2023-02-10","current":-1.719942,"twenty":-14.767548,"median":-5.325305,"eighty":-2.465003,"marketCap":167854292},{"date":"2023-02-17","current":-1.598056,"twenty":-14.638832,"median":-5.295802,"eighty":-2.294544,"marketCap":155959106},{"date":"2023-02-24","current":-1.442313,"twenty":-14.517074,"median":-5.28105,"eighty":-2.219541,"marketCap":140759701},{"date":"2023-03-03","current":-1.449085,"twenty":-14.054392,"median":-5.266709,"eighty":-2.138936,"marketCap":141420545},{"date":"2023-03-10","current":-1.259485,"twenty":-13.803918,"median":-5.257251,"eighty":-2.004618,"marketCap":122916922},{"date":"2023-03-17","current":-1.259485,"twenty":-13.049016,"median":-5.222044,"eighty":-1.906833,"marketCap":122916922},{"date":"2023-03-24","current":-1.151142,"twenty":-12.765494,"median":-5.214668,"eighty":-1.859433,"marketCap":112343423},{"date":"2023-03-31","current":-1.006921,"twenty":-12.62808,"median":-5.195674,"eighty":-1.814742,"marketCap":100004349},{"date":"2023-04-06","current":-0.993584,"twenty":-12.403697,"median":-5.18509,"eighty":-1.790365,"marketCap":98679788},{"date":"2023-04-14","current":-1.153624,"twenty":-12.106258,"median":-5.17779,"eighty":-1.734306,"marketCap":114574519},{"date":"2023-04-21","current":-1.086941,"twenty":-11.986239,"median":-5.165231,"eighty":-1.693089,"marketCap":107951714},{"date":"2023-04-28","current":-1.062043,"twenty":-11.596613,"median":-5.154405,"eighty":-1.669474,"marketCap":105478911},{"date":"2023-05-05","current":-1.115479,"twenty":-11.092,"median":-5.126159,"eighty":-1.604589,"marketCap":110786026},{"date":"2023-05-12","current":-1.662065,"twenty":-10.241261,"median":-5.114492,"eighty":-1.592633,"marketCap":117419920},{"date":"2023-05-18","current":-1.662065,"twenty":-10.005621,"median":-5.08928,"eighty":-1.592633,"marketCap":117419920},{"date":"2023-05-26","current":-1.605724,"twenty":-9.707425,"median":-5.066683,"eighty":-1.590375,"marketCap":113439583},{"date":"2023-06-02","current":-1.577553,"twenty":-9.509003,"median":-5.05675,"eighty":-1.577553,"marketCap":111449415},{"date":"2023-06-07","current":-1.586944,"twenty":-9.43545,"median":-5.053605,"eighty":-1.577553,"marketCap":112112805},{"date":"2023-06-16","current":-1.464871,"twenty":-9.370943,"median":-5.035235,"eighty":-1.563286,"marketCap":103488743},{"date":"2023-06-23","current":-1.42731,"twenty":-9.282028,"median":-5.023162,"eighty":-1.535759,"marketCap":100835185},{"date":"2023-06-30","current":-1.324018,"twenty":-9.164912,"median":-5.015391,"eighty":-1.507486,"marketCap":93537902},{"date":"2023-07-07","current":-1.699626,"twenty":-9.072816,"median":-4.992228,"eighty":-1.507486,"marketCap":120073477},{"date":"2023-07-14","current":-1.699626,"twenty":-8.996105,"median":-4.978644,"eighty":-1.50685,"marketCap":120073477},{"date":"2023-07-21","current":-1.680846,"twenty":-8.922199,"median":-4.962275,"eighty":-1.50685,"marketCap":118746699},{"date":"2023-07-28","current":-1.605724,"twenty":-8.822663,"median":-4.956516,"eighty":-1.50685,"marketCap":113439583},{"date":"2023-08-04","current":-1.577553,"twenty":-8.779783,"median":-4.941765,"eighty":-1.50685,"marketCap":111449415},{"date":"2023-08-11","current":-2.38569,"twenty":-8.747969,"median":-4.933588,"eighty":-1.50685,"marketCap":113439583},{"date":"2023-08-18","current":-2.35532,"twenty":-8.735869,"median":-4.904886,"eighty":-1.50685,"marketCap":99483990},{"date":"2023-08-25","current":-2.339512,"twenty":-8.649934,"median":-4.879071,"eighty":-1.50685,"marketCap":98816312},{"date":"2023-09-01","current":-2.371127,"twenty":-8.539552,"median":-4.870065,"eighty":-1.50685,"marketCap":100151668},{"date":"2023-09-08","current":-2.181437,"twenty":-8.281298,"median":-4.838504,"eighty":-1.50685,"marketCap":92139535},{"date":"2023-09-15","current":-2.181437,"twenty":-7.808558,"median":-4.797468,"eighty":-1.50685,"marketCap":92139535},{"date":"2023-09-22","current":-2.118207,"twenty":-7.690618,"median":-4.694622,"eighty":-1.50685,"marketCap":89468823},{"date":"2023-09-29","current":-2.023362,"twenty":-7.570553,"median":-4.543378,"eighty":-1.50685,"marketCap":85462757},{"date":"2023-10-06","current":-1.944324,"twenty":-7.460249,"median":-4.47683,"eighty":-1.50685,"marketCap":82124368},{"date":"2023-10-13","current":-1.896902,"twenty":-7.296875,"median":-4.400739,"eighty":-1.50685,"marketCap":80121334},{"date":"2023-10-20","current":-2.118207,"twenty":-7.080972,"median":-4.345558,"eighty":-1.50685,"marketCap":89468823},{"date":"2023-10-27","current":-1.786249,"twenty":-6.897329,"median":-4.267384,"eighty":-1.50685,"marketCap":75447590},{"date":"2023-11-03","current":-1.849479,"twenty":-6.768204,"median":-4.253588,"eighty":-1.50685,"marketCap":78118301},{"date":"2023-11-10","current":-5.023281,"twenty":-6.674971,"median":-4.240889,"eighty":-1.50685,"marketCap":80121334},{"date":"2023-11-17","current":-8.487937,"twenty":-6.669198,"median":-4.240889,"eighty":-1.50685,"marketCap":86415686},{"date":"2023-11-24","current":-8.948523,"twenty":-6.669198,"median":-4.240889,"eighty":-1.50685,"marketCap":91104909},{"date":"2023-12-01","current":-9.145917,"twenty":-6.669198,"median":-4.240889,"eighty":-1.50685,"marketCap":93114576},{"date":"2023-12-08","current":-9.606502,"twenty":-6.671374,"median":-4.24264,"eighty":-1.50685,"marketCap":97803799},{"date":"2023-12-15","current":-9.6723,"twenty":-6.669198,"median":-4.240889,"eighty":-1.50685,"marketCap":98473688},{"date":"2023-12-22","current":-9.277512,"twenty":-6.669198,"median":-4.240889,"eighty":-1.50685,"marketCap":94454354},{"date":"2023-12-29","current":-10.165785,"twenty":-6.658855,"median":-4.238628,"eighty":-1.50685,"marketCap":103497856},{"date":"2024-01-05","current":-10.198684,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":103832801},{"date":"2024-01-12","current":-11.119855,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":113211247},{"date":"2024-01-19","current":-11.054057,"twenty":-6.64075,"median":-4.231182,"eighty":-1.50685,"marketCap":112541358},{"date":"2024-01-26","current":-10.067088,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":102493023},{"date":"2024-02-02","current":-10.067088,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":102493023},{"date":"2024-02-09","current":-9.606502,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":97803799},{"date":"2024-02-16","current":-9.869694,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":100483356},{"date":"2024-02-23","current":-9.738098,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":99143577},{"date":"2024-03-01","current":-16.1205,"twenty":-6.658855,"median":-4.238628,"eighty":-1.50685,"marketCap":164122814},{"date":"2024-03-08","current":-16.844278,"twenty":-6.658855,"median":-4.238628,"eighty":-1.50685,"marketCap":171491594},{"date":"2024-03-15","current":-245.178585,"twenty":-6.658855,"median":-4.238628,"eighty":-1.50685,"marketCap":139506615},{"date":"2024-03-22","current":-266.601956,"twenty":-6.658855,"median":-4.238628,"eighty":-1.50685,"marketCap":151696513},{"date":"2024-03-28","current":-260.689917,"twenty":-6.658855,"median":-4.238628,"eighty":-1.50685,"marketCap":148332563},{"date":"2024-04-05","current":-245.215172,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":139527433},{"date":"2024-04-12","current":-255.928457,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":145623292},{"date":"2024-04-19","current":-205.93313,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":117175951},{"date":"2024-04-26","current":-190.458387,"twenty":-6.658855,"median":-4.238628,"eighty":-1.50685,"marketCap":108370822},{"date":"2024-05-03","current":-535.664214,"twenty":-6.658855,"median":-4.238628,"eighty":-1.50685,"marketCap":304792938},{"date":"2024-05-10","current":8.357394,"twenty":-6.64746,"median":-4.217605,"eighty":-1.472316,"marketCap":138172798},{"date":"2024-05-17","current":8.193524,"twenty":-6.64746,"median":-4.155757,"eighty":-1.455856,"marketCap":135463528},{"date":"2024-05-24","current":8.624717,"twenty":-6.64746,"median":-4.086161,"eighty":-1.44458,"marketCap":142592445},{"date":"2024-05-31","current":8.24768,"twenty":-6.64746,"median":-4.078366,"eighty":-1.425186,"marketCap":136358895},{"date":"2024-06-07","current":7.870643,"twenty":-6.64746,"median":-4.044422,"eighty":-1.381595,"marketCap":130125346},{"date":"2024-06-14","current":6.880922,"twenty":-6.649081,"median":-4.02817,"eighty":-1.363555,"marketCap":113762278},{"date":"2024-06-21","current":6.032589,"twenty":-6.650702,"median":-3.970254,"eighty":-1.332765,"marketCap":99736792},{"date":"2024-06-28","current":5.93833,"twenty":-6.658855,"median":-3.954687,"eighty":-1.325927,"marketCap":98178404},{"date":"2024-07-05","current":6.126848,"twenty":-6.658855,"median":-3.93891,"eighty":-1.323047,"marketCap":101295179},{"date":"2024-07-12","current":6.598144,"twenty":-6.653992,"median":-3.9179,"eighty":-1.302891,"marketCap":109087116},{"date":"2024-07-15","current":6.692403,"twenty":-6.653992,"median":-3.9179,"eighty":-1.298362,"marketCap":110645503},{"date":"2024-08-02","current":6.315366,"twenty":-6.689358,"median":-3.816355,"eighty":-1.266142,"marketCap":104411954},{"date":"2024-08-09","current":8.314881,"twenty":-6.689358,"median":-3.774712,"eighty":-1.247243,"marketCap":92178769},{"date":"2024-08-16","current":8.385346,"twenty":-6.689358,"median":-3.738504,"eighty":-1.230576,"marketCap":92959945},{"date":"2024-08-23","current":8.385346,"twenty":-6.689358,"median":-3.711348,"eighty":-1.212085,"marketCap":92959945},{"date":"2024-08-30","current":8.103486,"twenty":-6.689358,"median":-3.684192,"eighty":-1.202123,"marketCap":89835241},{"date":"2024-09-06","current":8.314881,"twenty":-6.689358,"median":-3.65026,"eighty":-1.178228,"marketCap":92178769},{"date":"2024-09-13","current":8.808136,"twenty":-6.689358,"median":-3.616096,"eighty":-1.164056,"marketCap":97647001},{"date":"2024-09-20","current":8.244416,"twenty":-6.689358,"median":-3.581932,"eighty":-1.153624,"marketCap":91397593},{"date":"2024-09-27","current":8.455811,"twenty":-6.689358,"median":-3.549144,"eighty":-1.151142,"marketCap":93741121},{"date":"2024-10-04","current":7.962555,"twenty":-6.689358,"median":-3.547642,"eighty":-1.145218,"marketCap":88272889},{"date":"2024-10-11","current":7.89209,"twenty":-6.689358,"median":-3.547642,"eighty":-1.138105,"marketCap":87491713},{"date":"2024-10-18","current":8.173951,"twenty":-6.689358,"median":-3.547642,"eighty":-1.133619,"marketCap":90616417},{"date":"2024-10-25","current":7.61023,"twenty":-6.689358,"median":-3.547642,"eighty":-1.123879,"marketCap":84367009},{"date":"2024-10-31","current":6.990137,"twenty":-6.689358,"median":-3.547642,"eighty":-1.123212,"marketCap":77492660},{"date":"2024-11-08","current":5.648417,"twenty":-6.689382,"median":-3.557463,"eighty":-1.116693,"marketCap":78117601},{"date":"2024-11-15","current":5.658632,"twenty":-6.689382,"median":-3.557463,"eighty":-1.109597,"marketCap":78258879},{"date":"2024-11-22","current":4.903204,"twenty":-6.689382,"median":-3.557463,"eighty":-1.103501,"marketCap":67811318},{"date":"2024-11-29","current":5.99815,"twenty":-6.689382,"median":-3.557463,"eighty":-1.100278,"marketCap":82954411},{"date":"2024-12-06","current":6.564013,"twenty":-6.689382,"median":-3.557463,"eighty":-1.089994,"marketCap":90780299},{"date":"2024-12-13","current":6.337668,"twenty":-6.689382,"median":-3.557463,"eighty":-1.088313,"marketCap":87649944},{"date":"2024-12-20","current":6.224495,"twenty":-6.689382,"median":-3.524056,"eighty":-1.083428,"marketCap":86084766},{"date":"2024-12-27","current":6.394254,"twenty":-6.689382,"median":-3.50315,"eighty":-1.075266,"marketCap":88432533},{"date":"2025-01-03","current":5.99815,"twenty":-6.689382,"median":-3.466942,"eighty":-1.066973,"marketCap":82954411},{"date":"2025-01-10","current":5.561303,"twenty":-6.689406,"median":-3.432284,"eighty":-1.062686,"marketCap":76912826},{"date":"2025-01-17","current":4.793427,"twenty":-6.689406,"median":-3.407046,"eighty":-1.052912,"marketCap":66293096},{"date":"2025-01-24","current":4.910561,"twenty":-6.689406,"median":-3.383641,"eighty":-1.045009,"marketCap":67913055},{"date":"2025-01-31","current":4.951303,"twenty":-6.689406,"median":-3.339237,"eighty":-1.04102,"marketCap":68476519},{"date":"2025-02-07","current":4.92301,"twenty":-6.689406,"median":-3.312429,"eighty":-1.030008,"marketCap":68085224},{"date":"2025-02-14","current":4.675727,"twenty":-6.689406,"median":-3.262613,"eighty":-1.023149,"marketCap":64665311},{"date":"2025-02-21","current":4.618009,"twenty":-6.689406,"median":-3.171091,"eighty":-1.017181,"marketCap":63867071},{"date":"2025-02-28","current":3.820708,"twenty":-6.689406,"median":-2.946017,"eighty":-1.014294,"marketCap":52840395},{"date":"2025-03-07","current":3.493073,"twenty":-6.68943,"median":-2.758827,"eighty":-1.008519,"marketCap":48309206},{"date":"2025-03-14","current":1.484923,"twenty":-6.68943,"median":-2.592432,"eighty":-0.997777,"marketCap":47323014},{"date":"2025-03-21","current":1.67368,"twenty":-6.68943,"median":-2.592432,"eighty":-0.993872,"marketCap":53338516},{"date":"2025-03-28","current":1.549769,"twenty":-6.68943,"median":-2.38569,"eighty":-0.983881,"marketCap":49389591},{"date":"2025-04-04","current":1.365033,"twenty":-6.68943,"median":-2.35532,"eighty":-0.968301,"marketCap":43502249},{"date":"2025-04-11","current":1.243133,"twenty":-6.689406,"median":-2.315801,"eighty":-0.959836,"marketCap":39617405},{"date":"2025-04-16","current":1.587219,"twenty":-6.689406,"median":-2.286059,"eighty":-0.953028,"marketCap":50583079}],"updateTime":1744954128773}}}